Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review
BJU International, 05/04/2012MacDonald R et al.
Serenoa repens therapy does not improve lower urinary tract symptoms or maximum urinary flow rate compared with placebo in men with benign prostatic hyperplasia, even at double and triple the usual dose. Adverse events were generally mild and comparable to placebo.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.